Bac-in-a-box(r) bioencapsulation technology for enhanced probiotic viability
Austrianova's Bac-in-a-Box(R) technology offers a novel encapsulation solution, enhancing probiotic viability during storage and low pH exposure. This innovative approach extends shelf-life and protects probiotics in stomach acid, suitable for food and beverage applications.
Overview
Bac-in-a-Box(R) by Austrianova is an advanced bioencapsulation technology designed to enhance the viability of probiotics during storage and under low pH conditions, such as those found in the stomach. This solution addresses key challenges in probiotic delivery, ensuring extended shelf-life and effective delivery to the intestine. The microbeads protect probiotics in stomach acid and bile for up to 4 hours, making them ideal for integration into food and beverage products.
Technical specifications
- Encapsulation technology: Probiotic strains are encapsulated in cellulose microbeads, which are cultured until full, ensuring high-density bacterial loading.
- Shelf-life extension: The microbeads can be freeze-dried, significantly increasing the shelf-life of probiotic products to potentially up to 2 years.
- Acid protection: Provides up to 90% protection with minimal viability loss in acidic environments, enhancing gut colonization.
- Manufacturing standards: Capable of GMP production with a GRAS dossier for review, ensuring safety and compliance.
Technology readiness level
Bac-in-a-Box(R) is at TRL 7, having been tested in human nutritional studies, applied in animal feeds, and used in medical applications with patients. The technology is ready for broader commercial deployment, with established protocols for low pH testing and shelf-life studies.
About Austrianova Singapore Pte Ltd
Austrianova is a biotechnology company headquartered in Singapore that specializes in cell encapsulation technology. The company has developed proprietary platforms, including Cell-in-a-Box and Bac-in-a-Box, which create porous capsules around living cells, bacteria, or yeast. This encapsulation protects the contents from external environments while allowing for the free diffusion of nutrients, waste, and synthesized biological molecules. These technologies are designed to facilitate the storage, transport, and therapeutic application of living cells for various medical and biological uses. In addition to its encapsulation platforms, the company provides comprehensive cell R&D services, including standardized allogenic cell therapy development, cell line engineering, and GMP-compliant cell banking.
By providing these technologies and services, Austrianova supports partners in the pharmaceutical and biotechnology sectors in developing innovative therapeutics, including treatments for cancer and age-related conditions. The company’s solutions enable the use of standardized cell products that do not require a patient's own cells, potentially streamlining clinical applications. Austrianova’s work is supported by extensive peer-reviewed research and international collaborations. The company maintains an international presence, with operations in Singapore and a European base in Germany, serving as a B2B partner for firms requiring expert cell biology services and specialized manufacturing capabilities under high quality and safety standards.
delivered to your inbox.